293 related articles for article (PubMed ID: 28490629)
1. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
[TBL] [Abstract][Full Text] [Related]
2. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
3. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization.
Sanders MA; Brahemi G; Nangia-Makker P; Balan V; Morelli M; Kothayer H; Westwell AD; Shekhar MPV
Mol Cancer Ther; 2013 Apr; 12(4):373-83. PubMed ID: 23339190
[TBL] [Abstract][Full Text] [Related]
4. Nano-delivery of
Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
[TBL] [Abstract][Full Text] [Related]
5. Rad6/Rad18 Competes with DNA Polymerases η and δ for PCNA Encircling DNA.
Li M; Larsen L; Hedglin M
Biochemistry; 2020 Feb; 59(4):407-416. PubMed ID: 31887036
[TBL] [Abstract][Full Text] [Related]
6. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Haynes B; Zhang Y; Liu F; Li J; Petit S; Kothayer H; Bao X; Westwell AD; Mao G; Shekhar MPV
Nanomedicine; 2016 Apr; 12(3):745-757. PubMed ID: 26563438
[TBL] [Abstract][Full Text] [Related]
8. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Oncogene; 2004 Apr; 23(17):3097-106. PubMed ID: 14981545
[TBL] [Abstract][Full Text] [Related]
9. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
10. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
12. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Rad6/Rad18 Activity During DNA Damage Tolerance.
Hedglin M; Benkovic SJ
Annu Rev Biophys; 2015; 44():207-28. PubMed ID: 26098514
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
Haynes B; Saadat N; Myung B; Shekhar MP
Mutat Res Rev Mutat Res; 2015; 763():258-66. PubMed ID: 25795124
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
[TBL] [Abstract][Full Text] [Related]
16. Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage.
Gregory MT; Park GY; Johnstone TC; Lee YS; Yang W; Lippard SJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9133-8. PubMed ID: 24927576
[TBL] [Abstract][Full Text] [Related]
17. Replication protein A dynamically regulates monoubiquitination of proliferating cell nuclear antigen.
Hedglin M; Aitha M; Pedley A; Benkovic SJ
J Biol Chem; 2019 Mar; 294(13):5157-5168. PubMed ID: 30700555
[TBL] [Abstract][Full Text] [Related]
18. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
[TBL] [Abstract][Full Text] [Related]
19. NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis.
Yanagihara H; Kobayashi J; Tateishi S; Kato A; Matsuura S; Tauchi H; Yamada K; Takezawa J; Sugasawa K; Masutani C; Hanaoka F; Weemaes CM; Mori T; Zou L; Komatsu K
Mol Cell; 2011 Sep; 43(5):788-97. PubMed ID: 21884979
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
